Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24498738 | 0.90 | KAT2B (0.43) | KAT2BBAZ2BADRB2ADRB1ADRB3 | |
| SCHEMBL22871103 | 0.88 | ADRA2A (0.44) | KAT2BBAZ2BADRB2ADRB1ADRB3 | |
| SCHEMBL22040926 | 0.84 | KAT2B (0.45) | KAT2BBAZ2BADRB2ADRB1ADRB3 | |
| SCHEMBL15077043 | 0.84 | PDE4A (0.42) | ADRB2ADRB1ADRB3PDE3BPDE3A | |
| SCHEMBL8059443 | 0.83 | KAT2B (0.49) | KAT2BBAZ2BSYKPDE4DPDE4A | |
| SCHEMBL22426537 | 0.83 | CARM1 (0.43) | ADRB2ADRB1ADRB3PDE3BPDE3A | |
| SCHEMBL24498230 | 0.83 | NISCH (0.40) | KAT2BBAZ2BADRB2ADRB1ADRB3 | |
| SCHEMBL17972910 | 0.83 | CARM1 (0.43) | ADRB2ADRB1ADRB3PDE3BPDE3A | |
| SCHEMBL24499265 | 0.81 | SYK (0.48) | KAT2BBAZ2BSYKPDE4DPDE4A | |
| SCHEMBL3126948 | 0.80 | HTR1A (0.43) | KAT2BBAZ2BADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | KAT2B 4291/4885BAZ2B 3717/4885ADRB2 3343/4885 |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | KAT2B 2804/4885BAZ2B 1374/4885ADRB2 4447/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | KAT2B 2407/4885BAZ2B 2212/4885ADRB2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.